Overview

Study of Arimoclomol in Inclusion Body Myositis (IBM)

Status:
Completed
Trial end date:
2021-01-11
Target enrollment:
Participant gender:
Summary
Funding Source - FDA OOPD. The purpose of this study is to evaluate the safety and efficacy of the study drug, Arimoclomol in IBM patients.
Phase:
Phase 2
Details
Lead Sponsor:
Orphazyme
University of Kansas Medical Center
Collaborators:
University College, London
University of Kansas Medical Center